Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of DW6013 FDC vs Loose Combination in Healthy Fed Adults
NCT05874180Phase 1Completed
- Sponsor
- Dongwha Pharmaceutical Co., Ltd.
- Start
- Jan 2023
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of linagliptin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dongwha Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration up to 48 hours and Maximum Plasma Concentration up to 48 hours. Started Jan 2023; status: completed.
02
Drugs
linagliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05874180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05874180.